Document Detail

Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
MedLine Citation:
PMID:  19349712     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIM: The aim of this prospective controlled study was to compare the effects of two therapies for menopause on factor VII (FVII) and hemostatic variables. METHODS: Postmenopausal women were assigned to receive one of the following treatments: transdermal estradiol (TTS E2; 50 microg) combined in a continuous sequential regimen with oral medroxyprogesterone acetate (MPA; 10 mg/day for 12 days) (group A; n = 20), tibolone (2.5 mg/day) (group B; n = 21) or placebo (group C; n = 19). Sixty women completed the 1-year treatment and underwent follow-up examinations after 3, 6 and 12 months. RESULTS: TTS E2/MPA induced various changes in procoagulatory factors. At 12 months, fibrinogen, activated FVII (FVIIa) and coagulative FVII (FVIIc) had increased by 10.7, 12.9 and 3.7%, respectively. Among the fibrinolytic factors, plasminogen and alpha2-antiplasmin increased by 11.3 and 7.2%, respectively. Lipoprotein(a) [Lp(a)] and antithrombin III (ATIII) did not show any significant variation. Tibolone induced some changes toward a more homogeneous antithrombotic profile. Fibrinogen, FVIIa and FVIIc decreased significantly by 7.5, 8.1 and 21.3%, respectively. Plasminogen increased (by 11.8%) and Lp(a) decreased (by 28.4%). ATIII was unchanged with tibolone therapy. CONCLUSION: Our results show that tibolone induces a significant reduction in FVIIc and Lp(a) and a greater enhancement of factors promoting fibrinolysis than the TTS E2/MPA regimen.
G Perrone; O Capri; P Galoppi; R Brunelli; E Bevilacqua; F Ceci; M V Ciarla; R Strom
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-04-07
Journal Detail:
Title:  Gynecologic and obstetric investigation     Volume:  68     ISSN:  1423-002X     ISO Abbreviation:  Gynecol. Obstet. Invest.     Publication Date:  2009  
Date Detail:
Created Date:  2009-07-22     Completed Date:  2009-10-15     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7900587     Medline TA:  Gynecol Obstet Invest     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  33-9     Citation Subset:  IM    
Department of Gynecology and Obstetrics, University Sapienza, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Administration, Oral
Analysis of Variance
Blood Coagulation Factors / drug effects
Estradiol / pharmacology*,  therapeutic use
Estrogen Receptor Modulators / pharmacology*,  therapeutic use
Estrogen Replacement Therapy / methods*
Factor VII / analysis
Fibrinolysis / drug effects
Follow-Up Studies
Lipoprotein(a) / analysis
Medroxyprogesterone Acetate / pharmacology*,  therapeutic use
Menopause / drug effects*
Middle Aged
Norpregnenes / pharmacology*,  therapeutic use
Prospective Studies
Reg. No./Substance:
0/Blood Coagulation Factors; 0/Estrogen Receptor Modulators; 0/Lipoprotein(a); 0/Norpregnenes; 50-28-2/Estradiol; 5630-53-5/tibolone; 71-58-9/Medroxyprogesterone Acetate; 9001-25-6/Factor VII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stiff person syndrome.
Next Document:  Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZh...